PEDIATRICS Vol. 99 No. 1 January 1997, pp. 93-99 (doi:10.1542/peds.99.1.93)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 99 No. 1 January 1997, pp. 93-99

Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis

Received May 28, 1996; accepted Aug 21, 1996.

The PREVENT Study Group

From the PREVENT Study Group.

Objective.  To determine the safety and efficacy of monthly prophylaxis with respiratory syncytial virus immune globulin, intravenous (RSV-IGIV) for reduction of the incidence of RSV-associated hospitalization.

Methods.  A randomized, double-blind, placebo-controlled clinical trial was conducted at 54 centers in the United States during the 1994 to 1995 RSV season. A total of 510 children with bronchopulmonary dysplasia and/or a history of prematurity were randomized to receive either 750 mg/kg RSV-IGIV (n = 250) or placebo (1% albumin; n = 260) intravenously every 30 days. Randomized groups were well balanced at entry for demographics, RSV risk factors, and birth characteristics. Children were monitored for adverse events and for RSV-associated hospitalization from randomization through 30 days after the last infusion visit; serious adverse events were monitored for an additional 30 days. For children hospitalized with RSV, data were collected regarding the total days of RSV stay, total days of increased oxygen requirement, total days with a moderate or severe lower respiratory tract illness, and frequency and duration of intensive care unit stay and mechanical ventilation. Ninety-five percent of participants completed the protocol and 85% received a complete course of infusions.

Results.  The incidence of RSV hospitalization was reduced by 41% in children receiving RSV-IGIV prophylaxis; 35 (13.5%) of the children in the placebo group were hospitalized for RSV, compared with 20 (8.0%) RSV-IGIV recipients. RSV-IGIV recipients had a 53% reduction in the total number of RSV hospital days per 100 children, a 60% reduction in the number of RSV days with increased oxygen requirement, and a 54% reduction in the number of RSV hospital days with a moderate or severe lower respiratory tract illness. In addition, children receiving RSV-IGIV had a 38% reduction in hospitalization for respiratory illness of any cause and a 46% reduction in total hospital days for respiratory illness per 100 children. RSV-IGIV was safe and well tolerated, with a safety profile similar to other IGIV preparations. Between 1% to 3% of children had medically significant adverse events related to RSV-IGIV administration.

Conclusions.  Monthly administration of 750 mg/kg of RSV-IGIV was safe and well tolerated and was effective in reducing the incidence and total days of both RSV hospitalization and overall respiratory hospitalization in infants with a history of prematurity or bronchopulmonary dysplasia or both.

Key words: respiratory syncytial virus, respiratory syncytial virus immune globulin, prophylaxis.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
S. S. Mohapatra and S. Boyapalle
Epidemiologic, Experimental, and Clinical Links between Respiratory Syncytial Virus Infection and Asthma
Clin. Microbiol. Rev., July 1, 2008; 21(3): 495 - 504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. A. Awomoyi, P. Rallabhandi, T. I. Pollin, E. Lorenz, M. B. Sztein, M. S. Boukhvalova, V. G. Hemming, J. C. G. Blanco, and S. N. Vogel
Association of TLR4 Polymorphisms with Symptomatic Respiratory Syncytial Virus Infection in High-Risk Infants and Young Children
J. Immunol., September 1, 2007; 179(5): 3171 - 3177.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
H. B. Panitch
The Relationship Between Early Respiratory Viral Infections and Subsequent Wheezing and Asthma
Clinical Pediatrics, June 1, 2007; 46(5): 392 - 400.
[PDF]

Home page
 J. Virol.Home page
X. Zhao, E. Liu, F.-P. Chen, and W. M. Sullender
In Vitro and In Vivo Fitness of Respiratory Syncytial Virus Monoclonal Antibody Escape Mutants
J. Virol., December 1, 2006; 80(23): 11651 - 11657.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
N. O. ElHassan, M. E. S. Sorbero, C. B. Hall, T. P. Stevens, and A. W. Dick
Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease.
Arch Pediatr Adolesc Med, October 1, 2006; 160(10): 1070 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. Marodi
Neonatal Innate Immunity to Infectious Agents
Infect. Immun., April 1, 2006; 74(4): 1999 - 2006.
[Full Text] [PDF]

Home page
 ThoraxHome page
S Broughton, A Roberts, G Fox, E Pollina, M Zuckerman, S Chaudhry, and A Greenough
Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants
Thorax, December 1, 2005; 60(12): 1039 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. V. Capparelli, B. T. Bloom, T. J. Kueser, D. G. Oelberg, E. M. Bifano, R. D. White, R. L. Schelonka, S. A. Pearlman, J. Patti, and S. V. Hetherington
Multicenter Study To Determine Antibody Concentrations and Assess the Safety of Administration of INH-A21, a Donor-Selected Human Staphylococcal Immune Globulin, in Low-Birth-Weight Infants
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4121 - 4127.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Prais, D. Danino, T. Schonfeld, J. Amir, and for the Israeli RSV Monitoring Group
Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis: A National Survey{dagger}
Chest, October 1, 2005; 128(4): 2765 - 2771.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
N D Embleton, C Harkensee, and M C Mckean
Palivizumab for preterm infants. Is it worth it?
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2005; 90(4): F286 - f289.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Y. Richardson, M. G. Ottolini, L. Pletneva, M. Boukhvalova, S. Zhang, S. N. Vogel, G. A. Prince, and J. C. G. Blanco
Respiratory Syncytial Virus (RSV) Infection Induces Cyclooxygenase 2: A Potential Target for RSV Therapy
J. Immunol., April 1, 2005; 174(7): 4356 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
A. Mejias, S. Chavez-Bueno, and P. J. Sanchez
Respiratory Syncytial Virus Prophylaxis
NeoReviews, January 1, 2005; 6(1): e26 - e31.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
T Lacaze-Masmonteil, P Truffert, D Pinquier, P Daoud, G Goldfarb, E Vicaut, and B Fauroux
Lower respiratory tract illness and RSV prophylaxis in very premature infants
Arch. Dis. Child., June 1, 2004; 89(6): 562 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. J. Easton, J. B. Domachowske, and H. F. Rosenberg
Animal Pneumoviruses: Molecular Genetics and Pathogenesis
Clin. Microbiol. Rev., April 1, 2004; 17(2): 390 - 412.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. A. Prince, J. J. Mond, D. D. Porter, K. C. Yim, S. J. Lan, and D. M. Klinman
Immunoprotective Activity and Safety of a Respiratory Syncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with a CpG Oligodeoxynucleotide Adjuvant
J. Virol., December 15, 2003; 77(24): 13156 - 13160.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner, S. S. Long, and Committee on Infectious Diseases, and Committee on
Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Pediatrics, December 1, 2003; 112(6): 1447 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. Prais, T. Schonfeld, and J. Amir
Admission to the Intensive Care Unit for Respiratory Syncytial Virus Bronchiolitis: A National Survey Before Palivizumab Use
Pediatrics, September 1, 2003; 112(3): 548 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Pediatr. Rev.Home page
C. A. McCarthy and C. B. Hall
Respiratory Syncytial Virus: Concerns and Control
Pediatr. Rev., September 1, 2003; 24(9): 301 - 309.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Statement on the Care of the Child with Chronic Lung Disease of Infancy and Childhood
Am. J. Respir. Crit. Care Med., August 1, 2003; 168(3): 356 - 396.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
K. J. Henrickson
Parainfluenza Viruses
Clin. Microbiol. Rev., April 1, 2003; 16(2): 242 - 264.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. M. Munoz, W. P. Glezen, R. Singleton, L. R. Bulkow, R. A. Karron, and L. H. Harrison
Why No Effect of Maternal Respiratory Syncytial Virus-Neutralizing Antibody?
Pediatrics, January 1, 2003; 111(1): 218 - 220.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
T. P. Klassen
Economic Evaluations of Immunoprophylaxis in Infants at High Risk for Respiratory Syncytial Virus: Shedding Light or Creating Confusion?
Arch Pediatr Adolesc Med, December 1, 2002; 156(12): 1180 - 1181.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
T. I. Shireman and K. S. Braman
Impact and Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis for Kansas Medicaid's High-Risk Children
Arch Pediatr Adolesc Med, December 1, 2002; 156(12): 1251 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
S. Kamal-Bahl, J. Doshi, and J. Campbell
Economic Analyses of Respiratory Syncytial Virus Immunoprophylaxis in High-Risk Infants: A Systematic Review
Arch Pediatr Adolesc Med, October 1, 2002; 156(10): 1034 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. G. Ottolini, S. J. Curtis, D. D. Porter, A. Mathews, J. Y. Richardson, V. G. Hemming, and G. A. Prince
Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats
Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2299 - 2302.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
F. Gigliotti, C. G. Haidaris, T. W. Wright, and A. G. Harmsen
Passive Intranasal Monoclonal Antibody Prophylaxis against Murine Pneumocystis carinii Pneumonia
Infect. Immun., March 1, 2002; 70(3): 1069 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E Drewe and R J Powell
Clinically useful monoclonal antibodies in treatment
J. Clin. Pathol., February 1, 2002; 55(2): 81 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
A Greenough, J Alexander, S Burgess, P A J Chetcuti, S Cox, W Lenney, F Turnbull, N J Shaw, A Woods, J Boorman, et al.
Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease
Arch. Dis. Child., January 1, 2002; 86(1): 40 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
A Greenough, S Cox, J Alexander, W Lenney, F Turnbull, S Burgess, P A J Chetcuti, N J Shaw, A Woods, J Boorman, et al.
Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection
Arch. Dis. Child., December 1, 2001; 85(6): 463 - 468.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. S. Giebink
The Prevention of Pneumococcal Disease in Children
N. Engl. J. Med., October 18, 2001; 345(16): 1177 - 1183.
[Full Text] [PDF]

Home page
 CVIHome page
V. G. Hemming
Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases
Clin. Vaccine Immunol., September 1, 2001; 8(5): 859 - 863.
[Full Text] [PDF]

Home page
 ChestHome page
S. Z. Nasr, P. J. Strouse, E. Soskolne, N. J. Maxvold, K. A. Garver, B. K. Rubin, and F. W. Moler
Efficacy of Recombinant Human Deoxyribonuclease I in the Hospital Management of Respiratory Syncytial Virus Bronchiolitis
Chest, July 1, 2001; 120(1): 203 - 208.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
F. W. Moler and T. P. Stevens
Cost Estimates of Prophylaxis
Arch Pediatr Adolesc Med, February 1, 2001; 155(2): 199 - 200.
[Full Text] [PDF]

Home page
 BMJHome page
and
Preventing respiratory syncitial virus
BMJ, January 13, 2001; 322(7278): 62 - 63.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Keller and E. R. Stiehm
Passive Immunity in Prevention and Treatment of Infectious Diseases
Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. Brunvand, R. Lindemann, J. Grøgaard;, E. M. Connor, D. Carlin, F. H. Top Jr., and L. E. Weisman
Who Shall Not Receive Palivizumab?
Pediatrics, October 1, 2000; 106(4): 866 - 866.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
M. Thomas, A. Bedford-Russell, and M. Sharland
Hospitalisation for RSV infection in ex-preterm infants---implications for use of RSV immune globulin
Arch. Dis. Child., August 1, 2000; 83(2): 122 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
W. LENNEY;, C. CARNEGIE;, and H. MARCOVITCH
Palivizumab and RSV prevention
Arch. Dis. Child., July 1, 2000; 83(1): 87a - 87.
[Full Text]

Home page
 PediatricsHome page
S. Joffe, T. A. Lieu, and G. J. Escobar
The Critical Role of Population-Based Epidemiology in Cost-Effectiveness Research
Pediatrics, April 1, 2000; 105(4): 862 - 863.
[Full Text]

Home page
 Clin. Microbiol. Rev.Home page
W. M. Sullender
Respiratory Syncytial Virus Genetic and Antigenic Diversity
Clin. Microbiol. Rev., January 1, 2000; 13(1): 1 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
T. P. Stevens, R. A. Sinkin, C. B. Hall, W. M. Maniscalco, and K. M. McConnochie
Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks' Gestation or Earlier: Hospitalization and Economic Implications of Prophylaxis
Arch Pediatr Adolesc Med, January 1, 2000; 154(1): 55 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S. DESHPANDE; and R M NICHOLL
RSV prevention
Arch. Dis. Child., January 1, 2000; 82(1): 88 - 88.
[Full Text]

Home page
 PediatricsHome page
J. R. Groothuis
The Pitfalls of Using Managed Care Databases in Cost-Effectiveness Research
Pediatrics, November 1, 1999; 104(5): 1124 - 1125.
[Full Text]

Home page
 PediatricsHome page
S. Joffe, G. J. Escobar, S. B. Black, M. A. Armstrong, and T. A. Lieu
Rehospitalization for Respiratory Syncytial Virus Among Premature Infants
Pediatrics, October 1, 1999; 104(4): 894 - 899.
[Abstract] [Full Text]

Home page
 PediatricsHome page
G. Suresh;, W. T. Zempsky, N. L. Schechter;, J. L. Fox;, E. M. Connor, D. Carlin, F. H. Top, J. MD, and L. E. Weisman
IMpact-RSV Study Group Report
Pediatrics, October 1, 1999; 104(4): 993 - 994.
[Full Text]

Home page
 PediatricsHome page
S. Joffe, G. T. Ray, G. J. Escobar, S. B. Black, and T. A. Lieu
Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm Infants
Pediatrics, September 1, 1999; 104(3): 419 - 427.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. W. Moler
RSV Immune Globulin Prophylaxis: Is an Ounce of Prevention Worth a Pound of Cure?
Pediatrics, September 1, 1999; 104(3): 559 - 560.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. Weltzin and T. P. Monath
Intranasal Antibody Prophylaxis for Protection against Viral Disease
Clin. Microbiol. Rev., July 1, 1999; 12(3): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
H. Plotnicky-Gilquin, L. Goetsch, T. Huss, T. Champion, A. Beck, J.-F. Haeuw, T. N. Nguyen, J.-Y. Bonnefoy, N. Corvaïa, and U. F. Power
Identification of Multiple Protective Epitopes (Protectopes) in the Central Conserved Domain of a Prototype Human Respiratory Syncytial Virus G Protein
J. Virol., July 1, 1999; 73(7): 5637 - 5645.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
H. C. Meissner, J. R. Groothuis, W. J. Rodriguez, R. C. Welliver, G. Hogg, P. H. Gray, R. Loh, E. A. F. Simoes, P. Sly, A. K. Miller, et al.
Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease
Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1183 - 1188.
[Abstract] [Full Text]

Home page
 Arch Pediatr Adolesc MedHome page
G. J. Redding, S. Braun, and D. Mayock
Impact of Respiratory Syncytial Virus Immune Globulin in 1996-1997: A Local Controlled Comparison
Arch Pediatr Adolesc Med, May 1, 1999; 153(5): 503 - 507.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. H. Balfour
Antiviral Drugs
N. Engl. J. Med., April 22, 1999; 340(16): 1255 - 1268.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. B. Domachowske and H. F. Rosenberg
Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment
Clin. Microbiol. Rev., April 1, 1999; 12(2): 298 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. W. MOLER and S. E. OHMIT
Severity Of Illness Models For Respiratory Syncytial Virus-Associated Hospitalization
Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1234 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. W. Moler, R. W. Brown, R. G. Faix, and J. R. Gilsdorf
Comments on Palivizumab (Synagis)
Pediatrics, February 1, 1999; 103(2): 495 - 496.
[Full Text]

Home page
 PediatricsHome page
S. C. Eppes;, S. L. Lee, J. L. Robinson;, E. M. Connor, D. Carlin, F. H. Top Jr, and L. E. Weisman
Questions About Palivizumab (Synagis)
Pediatrics, February 1, 1999; 103(2): 534 - 535.
[Full Text]

Home page
 PediatricsHome page
Committee on Infectious Diseases and Committee on
Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV
Pediatrics, November 1, 1998; 102(5): 1211 - 1216.
[Abstract] [Full Text]

Home page
 J. Clin. Microbiol.Home page
J. Stockton, J. S. Ellis, M. Saville, J. P. Clewley, and M. C. Zambon
Multiplex PCR for Typing and Subtyping Influenza and Respiratory Syncytial Viruses
J. Clin. Microbiol., October 1, 1998; 36(10): 2990 - 2995.
[Abstract] [Full Text]

Home page
 PediatricsHome page
The IMpact-RSV Study Group
Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
Pediatrics, September 1, 1998; 102(3): 531 - 537.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. A. Storch
Humanized Monoclonal Antibody for Prevention of Respiratory Syncytial Virus Infection
Pediatrics, September 1, 1998; 102(3): 648 - 651.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. A. Dudas and R. A. Karron
Respiratory Syncytial Virus Vaccines
Clin. Microbiol. Rev., July 1, 1998; 11(3): 430 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
J. M. Robbins, J. M. Tilford, R. F. Jacobs, J. G. Wheeler, S. R. Gillaspy, and G. E. Schutze
A Number-Needed-to-Treat Analysis of the Use of